RU2671485C2 - Антибиотические композиции тазобактама аргинина - Google Patents

Антибиотические композиции тазобактама аргинина Download PDF

Info

Publication number
RU2671485C2
RU2671485C2 RU2015115711A RU2015115711A RU2671485C2 RU 2671485 C2 RU2671485 C2 RU 2671485C2 RU 2015115711 A RU2015115711 A RU 2015115711A RU 2015115711 A RU2015115711 A RU 2015115711A RU 2671485 C2 RU2671485 C2 RU 2671485C2
Authority
RU
Russia
Prior art keywords
amino
methyl
carboxy
arginine
tazobactam
Prior art date
Application number
RU2015115711A
Other languages
English (en)
Russian (ru)
Other versions
RU2015115711A (ru
Inventor
Цзан-Цзи ЛАЙ
Цзянь-Цяо ГУ
ДАМУР Николь МИЛЛЕР
Прадип М. ПАТХАРЕ
Валдас Юркаускас
Джозеф ТЕРРАЧЧАНО
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of RU2015115711A publication Critical patent/RU2015115711A/ru
Application granted granted Critical
Publication of RU2671485C2 publication Critical patent/RU2671485C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
RU2015115711A 2012-09-27 2013-09-27 Антибиотические композиции тазобактама аргинина RU2671485C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706399P 2012-09-27 2012-09-27
US61/706,399 2012-09-27
PCT/US2013/062256 WO2014052799A1 (en) 2012-09-27 2013-09-27 Tazobactam arginine antibiotic compositions

Publications (2)

Publication Number Publication Date
RU2015115711A RU2015115711A (ru) 2016-11-20
RU2671485C2 true RU2671485C2 (ru) 2018-11-01

Family

ID=50389002

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015115711A RU2671485C2 (ru) 2012-09-27 2013-09-27 Антибиотические композиции тазобактама аргинина

Country Status (12)

Country Link
US (4) US20150306076A1 (enExample)
EP (1) EP2900244B1 (enExample)
JP (1) JP6186001B2 (enExample)
KR (1) KR102143256B1 (enExample)
CN (1) CN105025901B (enExample)
AU (2) AU2013323280A1 (enExample)
BR (1) BR112015006868B1 (enExample)
CA (1) CA2886402A1 (enExample)
IN (1) IN2015DN03113A (enExample)
MX (1) MX2015004039A (enExample)
RU (1) RU2671485C2 (enExample)
WO (1) WO2014052799A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) * 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101638311B1 (ko) * 2016-02-29 2016-07-12 (주)에프원테크놀로지 3축 코일 안테나의 단자부 및 이의 제조방법
MX2017013433A (es) * 2016-03-31 2018-01-30 Wockhardt Ltd Composiciones antibacterianas.
WO2017213944A1 (en) * 2016-06-06 2017-12-14 Merck Sharp & Dohme Corp. Solid forms of ceftolozane and processes for preparing
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559334A (en) * 1983-08-26 1985-12-17 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted-3-vinyl-3-cephem compounds and processes for production of the same
CN1236781A (zh) * 1999-01-12 1999-12-01 中国药品生物制品检定所 他唑巴坦半水合物的制备与应用
RU2397768C2 (ru) * 2004-12-02 2010-08-27 Венус Ремедиз Лимитед Композиции для преодоления опосредованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенные для инъекции

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648750B2 (ja) * 1988-03-02 1997-09-03 大塚化学株式会社 β−ラクタム誘導体の製造方法
AU679800B2 (en) * 1993-11-06 1997-07-10 Taiho Pharmaceutical Co., Ltd. Crystalline penicillin derivative, and its production and use
JP3743823B2 (ja) * 2000-08-11 2006-02-08 大塚化学ホールディングス株式会社 ペニシリン結晶及びその製造法
JP3306473B1 (ja) * 2001-05-01 2002-07-24 大塚化学株式会社 β−ラクタム化合物の無水結晶及びその製造法
JP2002338578A (ja) * 2001-05-14 2002-11-27 Otsuka Chem Co Ltd β−ラクタム化合物の水和物結晶
ATE368042T1 (de) 2002-10-30 2007-08-15 Astellas Pharma Inc Cephemverbindungen
AU2006297289B2 (en) * 2005-09-29 2013-03-21 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US20140275000A1 (en) * 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US8906898B1 (en) * 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559334A (en) * 1983-08-26 1985-12-17 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted-3-vinyl-3-cephem compounds and processes for production of the same
CN1236781A (zh) * 1999-01-12 1999-12-01 中国药品生物制品检定所 他唑巴坦半水合物的制备与应用
RU2397768C2 (ru) * 2004-12-02 2010-08-27 Венус Ремедиз Лимитед Композиции для преодоления опосредованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенные для инъекции

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Gazouli M. Effect of substitution of Asn for Arg-276 in the cefotaxime-hydrolyzing class A beta-lactamase CTX-M-4 // FEMS Microbiol Lett. - 1998. - 15; 169(2). - P. 289-293. *
Helio S. Sader. Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes // Antimicrob Agents Chemother. - 2011. - 55(5). - P. 2390-2394. *
Stapleton PD. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors // Antimicrob Agents Chemother.- 1999. - 43(8). - P. 1881-1887. *
Stapleton PD. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors // Antimicrob Agents Chemother.- 1999. - 43(8). - P. 1881-1887. Gazouli M. Effect of substitution of Asn for Arg-276 in the cefotaxime-hydrolyzing class A beta-lactamase CTX-M-4 // FEMS Microbiol Lett. - 1998. - 15; 169(2). - P. 289-293. *
И.С.Ажгихин. Технология лекарств. - 2 изд., перераб. и доп.- М.: Медицина. - 1980. - С. 440. *
И.С.Ажгихин. Технология лекарств. - 2 изд., перераб. и доп.- М.: Медицина. - 1980. - С. 440. Helio S. Sader. Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes // Antimicrob Agents Chemother. - 2011. - 55(5). - P. 2390-2394. *

Also Published As

Publication number Publication date
US20140206659A1 (en) 2014-07-24
JP6186001B2 (ja) 2017-08-23
AU2018203806B2 (en) 2020-04-02
EP2900244A4 (en) 2016-05-04
BR112015006868A2 (pt) 2017-07-04
JP2015531378A (ja) 2015-11-02
CN105025901B (zh) 2019-04-19
MX2015004039A (es) 2015-10-29
BR112015006868B1 (pt) 2021-11-30
AU2013323280A1 (en) 2015-04-09
CN105025901A (zh) 2015-11-04
CA2886402A1 (en) 2014-04-03
US20150306076A1 (en) 2015-10-29
KR102143256B1 (ko) 2020-08-11
US20140187528A1 (en) 2014-07-03
RU2015115711A (ru) 2016-11-20
EP2900244B1 (en) 2019-10-23
EP2900244A1 (en) 2015-08-05
WO2014052799A1 (en) 2014-04-03
AU2018203806A1 (en) 2018-06-21
KR20150070156A (ko) 2015-06-24
US20140213567A1 (en) 2014-07-31
IN2015DN03113A (enExample) 2015-10-02
BR112015006868A8 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
EP2900244B1 (en) Tazobactam arginine antibiotic compositions
US8685957B1 (en) Tazobactam arginine compositions
JP7177314B2 (ja) セフトロザン抗生物質組成物
US20140274996A1 (en) Tazobactam and ceftolozane antibiotic compositions
RU2524665C2 (ru) Композиции и способы лечения, включающие цефтаролин
WO2020184399A1 (ja) 抗菌用医薬組成物
WO2021049600A1 (ja) 抗菌作用を有する医薬組成物
AU2015200599B2 (en) Ceftolozane Antibiotic Compositions
CN111187281B (zh) 含胍基的头孢菌素衍生物及其制备方法
JPH04338392A (ja) 新規セフェム誘導体及びその製造方法
NZ711823B2 (en) Ceftolozane antibiotic compositions